Evidence mapPaperPMID 25054271Full record

ReviewExpert opinion on drug discovery2014

Novel approaches to drug discovery for the treatment of type 2 diabetes.

Xing Xu, Gaihong Wang, Tingting Zhou, Lili Chen, Jing Chen, Xu Shen

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Expert opinion on drug discovery, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02887677 (A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02887677 phase4terminatedstarted 2016, after this paper: background citation

A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes

Ran2016Enrolled85Registered outcomes9Posted comparisons0ConditionsDiabetes MellitusArmsdapagliflozin, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Antidiabetic Effects of the Ethanolic Root Extract ofAdvances in pharmacological sciences · 2018
    Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xing XuShanghai Institute of Materia Medica, Key Laboratory of Receptor Research, Chinese Academy of Sciences , 555 Zuchongzhi Road, Shanghai 201203 , China lilichen@simm.ac.cn ; jingchen@simm.ac.cn ; xshen@mail.shcnc.ac.cn.
Gaihong Wang
Tingting Zhou
Lili Chen
Jing Chen
Xu Shen
Chinese Academy of Sciences · CNShanghai Institute of Materia Medica · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionType 2 diabetes mellitus (T2DM) is a chronic, complex and multifactorial metabolic disorder, which has become a serious global health problem. The side effects of known drugs and the deficiency of long-term safety data, in addition to the already determined adverse effects for the current preclinical drugs against T2DM, have largely called upon the urgent exploration of novel therapeutic and preventative strategies against this disease. AREAS COVERED: The authors highlight the potential approaches for anti-T2DM drug discovery by focusing on: the restoration of pancreatic β-cell mass, the promotion of insulin secretion, the regulation of oxidative stress and endoplasmic reticulum (ER) stress and the modulation of autophagy. EXPERT OPINION: T2DM is based on the gradual development of insulin resistance and β-cell dysfunction. Thus, the restoration of β-cell function is considered as one of the promising therapeutic strategies against T2DM. The stress factors, such as oxidative stress, ER stress and autophagy, play potent roles in the regulation of β-cell apoptosis, insulin secretion and sensitivity in the development of T2DM involving complicated cross-talks. Based on multiplex stress-involved regulatory networks, more and more novel potential targets have been discovered and the multi-targeted drug leads are expected to help develop more effective clinical agents for the treatment of T2DM.

Indexed as

Drug DesignAnimalsDiabetes Mellitus, Type 2Drug DiscoveryHumansHypoglycemic AgentsInsulinInsulin ResistanceInsulin-Secreting CellsInsulin SecretionMolecular Targeted TherapyHypoglycemic AgentsInsulinautophagyendoplasmic reticulum stressinsulin secretionoxidative stresstype 2 diabetesβ-cell mass

Identifiers

PMID25054271
OpenAlexW2057600950

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.